Stergios B.
- Country
- Greece
- Department
- Oncology Department
Research Overview
- A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS<50% Non-squamous Non-small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung07)
- Phase 3 Randomized Study of Gedatolisib Combination Therapy versus Standard Endocrine Therapy in HR‑Positive, HER2‑Negative Advanced Breast Cancer Post‑CDK4/6 Inhibitor
- Phase II Open-Label Evaluation of Sacituzumab Govitecan in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma
Data & Insights
Has run more than one trial at 205 of 475 partner sites.
Specializations
Haematologic malignancies
Clinical research activity includes treatment strategies for multiple myeloma, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, small lymphocytic lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, acute myeloid leukemia, myelodysplastic neoplasms, myelofibrosis, and acute lymphoblastic leukemia.
- Relapsed and refractory plasma cell dyscrasias
- B-cell lymphoma and indolent lymphoma
- Myeloproliferative neoplasms
- Leukemia-directed therapy
The portfolio also extends to thrombocytopenia and thalassemia, reflecting interest in malignant and non-malignant blood disorders.
Cardiovascular and thrombotic disease
Research involvement spans atherosclerotic cardiovascular disease, acute myocardial infarction, acute ischemic stroke, atrial fibrillation, heart failure with reduced ejection fraction, hypertension, dyslipidaemia, and obesity associated cardiometabolic risk.
- Secondary prevention of cardiovascular events
- Stroke prevention
- Heart failure management
- Lipid-lowering and inflammation-targeted therapy
Additional interests include venous thrombosis, major adverse cardiovascular events, and lipoprotein(a)-related risk reduction.
Respiratory and inflammatory disorders
Clinical trial activity covers chronic obstructive pulmonary disease, asthma, bronchiectasis, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, progressive fibrosing interstitial lung disease, and severe viral lung infections.
- Airway inflammation
- Exacerbation prevention
- Pulmonary fibrosis
- Biologic therapy in respiratory disease
Work in this area also includes post-acute COVID syndrome and eosinophilic airway disease.
Kidney and immune-mediated disease
Research interests include chronic kidney disease, IgA nephropathy, idiopathic immune complex-mediated membranoproliferative glomerulonephritis, C3 glomerulopathy, proteinuria, and Fabry disease.
- Glomerular disease
- Renal protection
- Proteinuria reduction
- Inflammation-driven kidney disease
The investigator is also involved in immune system diseases such as idiopathic inflammatory myopathy and primary Sjogren's syndrome.
Neurology, oncology, and metabolic disease
Additional clinical interests include multiple sclerosis, refractory epilepsy, Alzheimer’s disease, agitation in dementia, breast cancer, non-small cell lung cancer, urothelial cancer, Crohn’s disease, ulcerative colitis, and type 2 diabetes.
- Neuroimmunology
- Solid tumours
- Inflammatory bowel disease
- Metabolic disease and obesity
Research activity also includes ocular disease such as age-related macular degeneration, glaucoma, and retinopathy of prematurity.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.